HOFSETH BIOCARE ASA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.09 NOK | -0.48% |
|
-2.79% | -20.23% |
| Mar. 14 | Hofseth BioCare ASA Announces Board Changes | CI |
| Feb. 09 | Hofseth BioCare ASA Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 707.6 | 2,932 | 3,507 | 2,469 | 1,300 | 1,035 |
| Enterprise Value (EV) 1 | 717.3 | 2,970 | 3,435 | 2,558 | 1,372 | 1,292 |
| P/E ratio | -7.27 x | -30.9 x | -31.6 x | -19.5 x | -8.89 x | -9.7 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 11.6 x | 43.3 x | 50.6 x | 28.2 x | 10.8 x | 4.74 x |
| EV / Revenue | 11.8 x | 43.8 x | 49.6 x | 29.2 x | 11.4 x | 5.91 x |
| EV / EBITDA | -12.5 x | -48.2 x | -43.5 x | -24.5 x | -11.6 x | -14.4 x |
| EV / FCF | -12 x | -61.8 x | -36.3 x | -37.5 x | -19 x | -12.8 x |
| FCF Yield | -8.31% | -1.62% | -2.75% | -2.67% | -5.27% | -7.81% |
| Price to Book | 8.16 x | 24.8 x | 13.3 x | 17.5 x | 8.74 x | 24.7 x |
| Nbr of stocks (in thousands) | 294,837 | 325,821 | 357,831 | 357,831 | 395,081 | 395,081 |
| Reference price 2 | 2.400 | 9.000 | 9.800 | 6.900 | 3.290 | 2.620 |
| Announcement Date | 3/15/19 | 3/20/20 | 3/19/21 | 3/25/22 | 3/31/23 | 4/19/24 |
1NOK in Million2NOK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 60.74 | 67.78 | 69.25 | 87.62 | 120.4 | 218.5 |
| EBITDA 1 | -57.51 | -61.65 | -79 | -104.6 | -118.6 | -89.83 |
| EBIT 1 | -77.7 | -79.57 | -92.02 | -118.6 | -128.6 | -102.5 |
| Operating Margin | -127.92% | -117.4% | -132.88% | -135.32% | -106.78% | -46.92% |
| Earnings before Tax (EBT) 1 | -84.53 | -89.22 | -102.1 | -126.5 | -137.4 | -106.7 |
| Net income 1 | -84.77 | -89.21 | -102.1 | -126.5 | -137.4 | -106.7 |
| Net margin | -139.56% | -131.62% | -147.42% | -144.34% | -114.06% | -48.82% |
| EPS 2 | -0.3300 | -0.2913 | -0.3100 | -0.3534 | -0.3700 | -0.2700 |
| Free Cash Flow 1 | -59.58 | -48.04 | -94.57 | -68.24 | -72.33 | -100.9 |
| FCF margin | -98.1% | -70.87% | -136.56% | -77.89% | -60.05% | -46.17% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/15/19 | 3/20/20 | 3/19/21 | 3/25/22 | 3/31/23 | 4/19/24 |
1NOK in Million2NOK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 9.66 | 37.9 | - | 89.3 | 71.7 | 257 |
| Net Cash position 1 | - | - | 72 | - | - | - |
| Leverage (Debt/EBITDA) | -0.168 x | -0.6149 x | - | -0.8536 x | -0.6047 x | -2.86 x |
| Free Cash Flow 1 | -59.6 | -48 | -94.6 | -68.2 | -72.3 | -101 |
| ROE (net income / shareholders' equity) | -138% | -87.6% | -53.5% | -62.6% | -95.3% | -113% |
| ROA (Net income/ Total Assets) | -26.1% | -20.7% | -15.3% | -16.9% | -19.4% | -16% |
| Assets 1 | 324.8 | 431.4 | 667.6 | 746.7 | 706.7 | 666.9 |
| Book Value Per Share 2 | 0.2900 | 0.3600 | 0.7400 | 0.3900 | 0.3800 | 0.1100 |
| Cash Flow per Share 2 | 0.1600 | 0.2900 | 0.4800 | 0.1400 | 0.0800 | 0.0600 |
| Capex 1 | 7.53 | 16.7 | 32.6 | 22.9 | 4.02 | 8.19 |
| Capex / Sales | 12.4% | 24.67% | 47.04% | 26.16% | 3.34% | 3.75% |
| Announcement Date | 3/15/19 | 3/20/20 | 3/19/21 | 3/25/22 | 3/31/23 | 4/19/24 |
1NOK in Million2NOK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -20.23% | 74.77M | |
| -4.93% | 261B | |
| -2.51% | 94.98B | |
| +3.19% | 46.39B | |
| +8.74% | 39.99B | |
| -0.15% | 38.02B | |
| -16.78% | 30.16B | |
| -6.61% | 28.72B | |
| +11.32% | 24.54B | |
| -9.29% | 22.65B |
- Stock Market
- Equities
- HBC Stock
- Financials Hofseth BioCare ASA
